Efficacy, safety, and pharmacokinetics of rifaximin in pediatric patients with hepatic encephalopathy in Japan: An open-label study.

Okajima H, Tagawa M, Fujisawa M, Ueda K

Open source

DOI
10.1097/hc9.0000000000001002
Published
2026 Aug 1
Container
Hepatology communications
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1097/hc9.0000000000001002,
  title = {Efficacy, safety, and pharmacokinetics of rifaximin in pediatric patients with hepatic encephalopathy in Japan: An open-label study.},
  author = {Okajima H and Tagawa M and Fujisawa M and Ueda K},
  year = {2026},
  journal = {Hepatology communications},
  doi = {10.1097/hc9.0000000000001002},
  url = {https://doi.org/10.1097/hc9.0000000000001002}
}

RIS

TY  - JOUR
TI  - Efficacy, safety, and pharmacokinetics of rifaximin in pediatric patients with hepatic encephalopathy in Japan: An open-label study.
AU  - Okajima H
AU  - Tagawa M
AU  - Fujisawa M
AU  - Ueda K
PY  - 2026
JO  - Hepatology communications
DO  - 10.1097/hc9.0000000000001002
UR  - https://doi.org/10.1097/hc9.0000000000001002
ER  - 

APA

H, O., M, T., M, F., & K, U. (2026). Efficacy, safety, and pharmacokinetics of rifaximin in pediatric patients with hepatic encephalopathy in Japan: An open-label study.. Hepatology communications. https://doi.org/10.1097/hc9.0000000000001002

Source records